Insider Buying: Mobia Medical (NASDAQ:MOBI) Director Purchases $203,417.10 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 17,166 shares of the company’s stock in a transaction on Monday, August 17th. The shares were acquired at an average price of $11.85 per share, with a total value of $203,417.10. Following the completion of the acquisition, the director directly owned 301,891 shares in the company, valued at $3,577,408.35. This represents a 6.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mobia Medical Price Performance

Shares of NASDAQ MOBI traded down $0.02 on Monday, hitting $11.74. The company’s stock had a trading volume of 98,126 shares, compared to its average volume of 92,796. The company has a 50 day simple moving average of $12.42. The stock has a market cap of $390.82 million and a P/E ratio of -0.61. Mobia Medical, Inc. has a 12-month low of $10.19 and a 12-month high of $15.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. The business’s revenue for the quarter was up 102.4% on a year-over-year basis. Sell-side analysts expect that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MOBI has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Bank of America initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price target for the company. Weiss Ratings initiated coverage on shares of Mobia Medical in a research note on Wednesday, August 12th. They set a “sell (e-)” rating on the stock. Wall Street Zen upgraded shares of Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Finally, Wolfe Research began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.